On June 24, 2013, the U.S. Supreme Court ruled that users of generic drugs cannot bring design-defect claims against generics makers under state law because, under federal law, generics' manufacturers cannot change a drug's design. The decision, in Mutual Pharmaceutical Co. Inc. v. Bartlett, "is a welcome development for both generic and brand companies," Austin Partner Susan Burnett told Law360.
Read the Law360 article.